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Bypass Surgery Versus Stenting for the Treatment of
Multivessel Disease in Patients With Unstable Angina
Compared With Stable Angina
P.J. de Feyter, MD; P.W. Serruys, MD; F. Unger, MD; R. Beyar, MD; V. de Valk, MSc; S. Milo, MD;
R. Simon, MD; D. Regensburger, MD; P.A. Crean, MD; E. McGovern, MD; P. van den Heuvel, MD;
C. van Cauwelaert, MD; I. Penn, MD; G.F.O. Tyers, MD; W. Lindeboom, MSc
Background—Earlier reports have shown that the outcome of balloon angioplasty or bypass surgery in unstable angina is
less favorable than in stable angina. Recent improvements in percutaneous treatment (stent implantation) and bypass
surgery (arterial grafts) warrant reevaluation of the relative merits of either technique in treatment of unstable angina.
Methods and Results—Seven hundred fifty-five patients with stable angina were randomly assigned to coronary stenting
(374) or bypass surgery (381), and 450 patients with unstable angina were randomly assigned to coronary stenting (226)
or bypass surgery (224). All patients had multivessel disease considered to be equally treatable by either technique.
Freedom from major adverse events, including death, myocardial infarction, and cerebrovascular events, at 1 year was
not different in unstable patients (91.2% versus 88.9%) and stable patients (90.4% versus 92.6%) treated, respectively,
with coronary stenting or bypass surgery. Freedom from repeat revascularization at 1 year was similar in unstable and
stable angina treated with stenting (79.2% versus 78.9%) or bypass surgery (96.3% versus 96%) but was significantly
higher in both unstable and stable patients treated with stenting (16.8% versus 16.9%) compared with bypass surgery
(3.6% versus 3.5%). Neither the difference in costs between stented or bypassed stable or unstable angina ($2594 versus
$3627) nor the cost-effectiveness was significantly different at 1 year.
Conclusions—There was no difference in rates of death, myocardial infarction, and cerebrovascular event at 1 year in
patients with unstable angina and multivessel disease treated with either stented angioplasty or bypass surgery compared
with patients with stable angina. The rate of repeat revascularization of both unstable and stable angina was significantly
higher in patients with stents. (Circulation. 2002;105:2367-2372.)
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There is uncertainty as to the appropriate intervention,bypass surgery or percutaneous intervention, required for
the treatment of unstable angina. Coronary artery bypass
surgery is highly effective in relieving ischemic symptoms,
but earlier studies reported a higher perioperative mortality
rate in unstable patients, particularly when performed early
after myocardial infarction (MI).1–4 Late survival and sus-
tained symptom relief is excellent after surgery for unstable
angina.5
Recent improvements in bypass surgery, notably the use of
arterial grafts, have made the procedure safer and more
effective, although the presence of instability at the time of
surgery is still a predictor of increased perioperative risk.6–10
Balloon angioplasty for unstable angina was less success-
ful and associated with a higher complication rate and late
restenosis rate compared with balloon angioplasty for stable
angina.11–15 The adjunctive treatment with platelet glycopro-
tein IIb/IIIa inhibitors has significantly reduced the 30-day
major complication rate,16–19 and the Evaluation of Platelet
IIb/IIIa Inhibitor for Stenting (EPI-STENT) trial demon-
strated that stent implantation combined with platelet glyco-
protein IIb/IIIa inhibitors for treatment of predominantly
single-vessel disease (90%) achieved similar results in unsta-
ble patients compared with stable patients.20
Recent randomized trials comparing surgery and percuta-
neous intervention for the treatment of multivessel disease
have shown that both treatments were associated with similar
death and MI rates, but they have not specifically addressed
the outcome in unstable patients compared with stable
patients.21–24
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In this prespecified subanalysis of the Arterial Revascular-
ization Therapies Study (ARTS) trial, the clinical outcomes,
costs, and cost-effectiveness of treatment of patients with
multivessel disease and unstable angina were compared with
those of patients with stable angina who were randomized to
either percutaneous coronary intervention (PCI) with stent




ARTS is a randomized trial comparing PCI versus CABG. Patients
with multivessel disease and a left ventricular ejection of at least
30% were included if they were deemed equally treatable with either
technique by consensus of cardiac surgeon and interventional cardi-
ologist. After providing written informed consent, the patients were
randomized to either CABG or PCI. Patients with left main stem
stenosis, prior CABG or PCI, transmural MI within the previous
week, history of prior cerebrovascular accident (CVA), concomitant
severe hepatic or renal disease, need for other major surgery,
intolerance or contraindication to acetyl salicylic acid or ticlopidine,
or presence of leucopenia, neutropenia, or thrombocytopenia were
excluded. Recruitment took place between April 1997 and June
1998. The clinical outcomes, costs, and cost-effectiveness are being
determined at 30 days and 1, 3, and 5 years. Details and results of the
main trial are provided elsewhere.25
Classification and Revascularization of Patients
Patients were classified as having stable angina (Canadian Cardio-
vascular Society class 1 through 4),26 silent ischemia, or unstable
angina (Braunwald classification I B, C through III B, C).27 They
must have had at least 2 de novo coronary lesions located in different
vessels. At least 1 stent per patient had to be implanted, but the total
number of stents was not restricted. For the purpose of this study, the
Cordis Palmaz Crown stent and the Crossflex stent were used for
stent implantation. Whenever feasible, the internal mammary artery
had to be used for revascularization of the left anterior descending
coronary artery or the diagonal branches.
End Points
The primary end point was defined as the absence of any of the
following major adverse cardiac and cerebrovascular events
(MACCE) within 12 months after randomization: death, CVA,
documented nonfatal MI, or repeat revascularization by PCI or










Male sex, % 75 80 77 75
Age, y (range) 6110 (35–83) 6110 (30–78) 6210 (32–81) 6110 (34–82)
Body mass index 284 274 284 274
Previous conditions, %
Q-wave MI 27 24 24 26
Non–Q-wave MI 16 22 15 22
Diabetes mellitus 19 19 17 15
Hypertension 42 49 46 43
Hypercholesterolemia 62 52 60 54
Family history 42 36 42 42
Smoking 70 74 74 71
Stable angina/silent ischemia CCS classification, %
1 8    8   
2 42    42   
3 35    37   
4 6    6   
Silent ischemia 10    8   
Unstable Braunwald, %
IB/IIB/IIIB    16/34/23    16/37/27
IC/IIC/IIIC    7/17/5    3/13/5
Ejection fraction, % 6112 6213 6213 5914
Number vessel diseased, %
2 69 67 65 64
3 31 33 35 36
Vessel territory, %
RCA 73 74 72 74
LAD 88 93 88 90
CX 69 67 73 73
There were no statistically significant differences between the 4 groups.
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CABG. All deaths, cardiac and noncardiac, were reported. Cerebro-
vascular events were classified into 3 categories: stroke, transient
ischemic attacks, and reversible ischemic neurological deficits. All
MIs were counted as events, whether occurring spontaneously or as
a periprocedural complication during PCI or CABG.
The Minnesota Code for pathological Q waves was used.28 The
serum levels of creatine kinase (CK) and CK muscular brain
(CK-MB) were sampled at 6, 12, and 18 hours after intervention, and
their ratios were calculated. Within the first 7 days after intervention,
a definite diagnosis of MI was made if new Q waves were
documented together with 1 sampled ratio of CK-MB 10% or 1
plasma level of CK-MB 5 times the upper limit of normal.29 After 7
days, either Q-wave or enzymatic elevation were sufficient as criteria
for MI.
A core laboratory analyzed relevant electrocardiograms, and the
diagnosis of MI was made after adjudication by a clinical event
committee. Repeat revascularization was performed if patients had
recurrent angina. The choice between (repeat) PCI and (repeat)
CABG was left to the discretion of the investigator.
Costs and cost-effectiveness of both techniques were compared at
1 year. Costs were limited to the direct medical costs per patient,
calculated as the product of each patient’s use of resources and the
corresponding unit cost. The cost-effectiveness was calculated using
MACCE event-free survival as the measure of effectiveness. The
incremental cost-effectiveness ratio is defined as the additional costs
per additional year of MACCE-free survival.
Statistical Analysis
Continuous variables were expressed as meanSD and were com-
pared using the unpaired Student’s t test. The Fisher’s exact test was
used for categorical variables. The Wilcoxon scores were used for
categorical variables with an ordinal scale. Discrete variables were
expressed as counts and percentages and were compared in terms of
relative risks (for CABG compared with PCI) with 95% CI.30 All
analyses were based on the intention-to-treat principle, and statistical
tests were 2-tailed. Event-free survival distribution was estimated
A, Actuarial survival. Kaplan-Meier estimates of survival without
CVA, MI, repeat CABG, or repeat PTCA. B, Survival without repeat
CABG or repeat PTCA. C, Survival without death, MI, or CVA
among stable and unstable patients undergoing stenting or CABG.
There was a statistically significant difference between stented
patients (either stable or unstable) and CABG patients (either stable
or unstable) except for in rate of survival with MI or CVA.










Total no. stenotic lesions
(50% diameter)
2.761.0 2.931.1 2.751.0 2.91.0
Actually treated or bypassed, n 2.591.1 2.761.2 2.661.0 2.641.0
Arterial conduit, n       1.10.54 1.110.6
Conduit to LAD, %       95 94
Lesions stented, n 2.360.95 2.380.92      
Balloon angioplasty, n 0.230.6 0.380.8      
LAD indicates left anterior descending coronary artery.
TABLE 3. Frequency of Major Cardiac Events Per Patient at 1
Year in Descending Order of Severity









Death 2.4 2.7 3.2 2.2
CVA 2.1 0.4 1.3 3.1
MI 5.1 5.8 2.9 5.8
Q-wave MI 4.3 5.3 2.9 4.9
Non–Q-wave MI 0.8 0.4 0 0.9
CABG* 3.7 6.2 0.3 0.9
Repeat PCI* 13.1 10.6 3.2 2.7
No MACCE† 73.5 74.3 89.2 85.3
*All bypass patients vs stented patients, P0.01.
†Stable and unstable angina bypass surgery vs stable and unstable stented
angioplasty, P0.0001.
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according to the Kaplan-Meier method, and the overall incidence of
MACCE was tested using the log-rank test.
Cost are expressed in United States dollars and calculated by
multiplying resource use, documented by the investigators, with unit
cost from the Netherlands. Incremental cost-effectiveness ratios were
expressed with 95% CIs.31
Results
A total of 1205 stable and unstable patients were randomly
assigned to stent implantation (total, 600 patients; stable, 374;
unstable, 226) or bypass surgery (total, 605 patients; stable,
381; unstable, 224). The baseline characteristics (demograph-
ic and angiographic) were not different among the 4 groups of
patients (Table 1). Most patients had 1 or more risk factors,
and two thirds of patients presently or formerly smoked. Only
8% to 10% had silent ischemia, and these patients were
classified as having stable angina. Most of the patients had a
significant obstruction of the left anterior descending coro-
nary artery.
Patients with unstable angina had a similar number of
stenotic lesions as those with stable angina (Table 2). The
number of treated stenoses was also not significantly different
among the 4 groups. As per protocol, the left anterior
descending artery was bypassed with the use of an arterial
conduit in almost all cases.
Clinical Outcomes
Absence of MACCE at 1 year in stented unstable patients was
not statistically different compared with stable patients and
surgically treated unstable and stable patients (Table 3 and
Figure, A). However, the patients, unstable or stable, who
underwent CABG had a significantly higher absence of
MACCE at 1 year compared with those who were stented.
This was mainly attributable to the higher frequency of
revascularizations in the stented group (Figure, C), whereas
there were no significant differences between the rates of
death, MI, or CVA (Figure, B).
Absence of MACCE at 1 year was not statistically different in
stented unstable patients classified according to Braunwald
classification (class I, 73%; class II, 74%; and class III, 77%) or
in bypass patients (class I, 88%; class II, 87%; class III, 81%).
At 1 year, 77%, 83%, 90%, and 89%, respectively, of the
stented patients with stable or unstable angina or bypassed
patients with stable or unstable angina were angina free. A
total of 18% of the stable and 21% of the unstable stented
patients were angina and medication free, compared with
42% of the stable and 34% of the unstable bypassed patients
(P0.003).
Cost
At the end of 1 year, the average total costs per patient with
stable angina were $12 960 for CABG versus $10 368 for
stenting (a difference of $2592) compared with $14 783
versus $11 156 (a difference of $3627) in patients with
unstable angina (Table 4). This difference in cost was largely
attributable to the higher costs of both the initial and
follow-up hospitalization.
There was no significant difference in MACCE event-free
survival between the 2 treatments, which was 11% for
unstable angina and 15.7% for stable angina (Table 4). The
incremental cost-effectiveness ratio in favor of stenting com-
pared with bypass surgery was $16 530 for patients with
stable angina compared with $32 983 for patients with
unstable angina.
Discussion
At the time of the conception of the ARTS trial, there were no
studies available about the relative merits of modern surgical
or percutaneous revascularization techniques with regard to
the outcome of treatment of multivessel disease in unstable
patients with angina compared with stable patients. The
ARTS trial offered the opportunity to investigate whether
there are differences in outcome between unstable and stable
patients undergoing either bypass surgery with arterial grafts
or percutaneous intervention with stent implantation.
This subanalysis demonstrated that there were no signifi-
cant differences in early and 1-year major adverse events
between patients with unstable and stable angina undergoing
TABLE 4. Costs and Cost-Effectiveness at 1 Year (Measured in US Dollars)
Stable Unstable
CABG Stent CABG Stent
Initial procedure 6504 5054 6823 5192
Initial hospitalization 3829 1173 4371 1605
Total procedure 10 333 6227 11 194 6797
Follow-up event diagnostic test 486 1433 488 1558
Rehospitalization 1537 1738 2395 1952
Total follow-up 2023 3171 2883 3510
Medication 604 970 705 849
Total direct medical cost 12 960 10 368 14 783 11 156
Difference in cost 2592 3627*
Difference in effectiveness percent 15.7 11.0
Incremental cost-effectiveness ratio† 16.530 (8.270–31.563) 32.983 (13.389–122.316)
*Difference not significant.
†95% CI.
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either treatment modality. However, the need for repeat
revascularization was significantly higher for both stable and
unstable patients undergoing stent implantation, whereas
there was no difference in repeat revascularization rate
between unstable and stable patients.
Earlier trials21 comparing balloon angioplasty without stent
implantation with CABG demonstrated that the difference of
freedom of MACCE between angioplasty and surgery was
30%, which was almost entirely attributable to the greater
need for repeat revascularization in the angioplasty group.
This 30% difference has now been reduced by half, to 11%
for unstable patients and 16% for stable patients, with the use
of stenting. Additional improvements in stent technology,
such as drug-eluting stents, may additionally reduce this
difference in event-free survival between PCI and CABG.32
The efficacy of new treatments must be weighed against
their costs. The respective difference in costs at 1 year was
less for stenting both in unstable patients ($3627) and stable
patients ($2592). This implies that if an approach of bypass
surgery rather than stenting was pursued, the cost of each
additional patient who survives event free would be $32 983
for unstable patients compared with $16 530 for stable
patients.
Limitations
The patients randomized in this study may not be represen-
tative of all patients with multivessel disease undergoing
revascularization procedures because of the prespecified in-
clusion and exclusion criteria and the requirement for a
consensus between cardiologist and surgeon on equal treat-
ability. This is further exemplified by the fact that only a
small portion of the total number of screened patients with
multivessel disease were actually enrolled in the study. In
addition, patients with significant left main disease and
patients with refractory unstable angina were excluded from
this study.
This study is a subanalysis, albeit prespecified, and hence
suffers from inherent limitations, such as the lack of sufficient
power because of the limited number of patients in the
subgroups to provide definite answers.
Conclusions
There is no difference in the rate of major adverse events in
unstable patients with multivessel disease treated with either
stented angioplasty or bypass surgery using arterial grafts
compared with stable patients. In addition, the need for repeat
revascularization in unstable patients undergoing stenting or
bypass surgery was similar compared with stable patients.
However, the overall need for repeat revascularization was
significantly higher in stented patients compared with bypass
surgery patients. The cost and cost-effectiveness in patients
with unstable angina was not different from stable angina,
although overall stenting was a cost-effective alternative to
surgery.
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